APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast 2026-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pulmonary Arterial Hypertension Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pulmonary Arterial Hypertension Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pulmonary Arterial Hypertension Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pulmonary Arterial Hypertension Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pulmonary Arterial Hypertension Treatment include GSK, Teva Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Bayer AG, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc and Actelion Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pulmonary Arterial Hypertension Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pulmonary Arterial Hypertension Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Pulmonary Arterial Hypertension Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Arterial Hypertension Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pulmonary Arterial Hypertension Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pulmonary Arterial Hypertension Treatment revenue, projected growth trends, production technology, application and end-user industry.

Pulmonary Arterial Hypertension Treatment Segment by Company

GSK

Teva Pharmaceuticals Inc

Eli Lilly and Company

Pfizer Inc

Bayer AG

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Actelion Inc

Pulmonary Arterial Hypertension Treatment Segment by Type

Vasodilators

Endothelin Receptor Antagonists (ERA)

Phosphodiesterase 5 (PDE 5) Inhibitors

Soluble Guanylate Cyclase (SGC) Stimulator

Pulmonary Arterial Hypertension Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Pulmonary Arterial Hypertension Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pulmonary Arterial Hypertension Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pulmonary Arterial Hypertension Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Arterial Hypertension Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vasodilators Major Player Table 3. Endothelin Receptor Antagonists (ERA) Major Player Table 4. Phosphodiesterase 5 (PDE 5) Inhibitors Major Player Table 5. Soluble Guanylate Cyclase (SGC) Stimulator Major Player Table 6. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacies Major Player Table 8. Online Pharmacies Major Player Table 9. Retail Pharmacies Major Player Table 10. Pulmonary Arterial Hypertension Treatment Industry Trends Table 11. Pulmonary Arterial Hypertension Treatment Industry Drivers Table 12. Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges Table 13. Pulmonary Arterial Hypertension Treatment Industry Restraints Table 14. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2021-2026) Table 17. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2027-2032) Table 19. Global Pulmonary Arterial Hypertension Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Pulmonary Arterial Hypertension Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Pulmonary Arterial Hypertension Treatment Key Players Headquarters & Area Served Table 23. Global Pulmonary Arterial Hypertension Treatment Players, Product Type & Application Table 24. Global Pulmonary Arterial Hypertension Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Pulmonary Arterial Hypertension Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Pulmonary Arterial Hypertension Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Pulmonary Arterial Hypertension Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2027-2032) Table 37. GSK Company Information Table 38. GSK Business Overview Table 39. GSK Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. GSK Pulmonary Arterial Hypertension Treatment Product Portfolio Table 41. GSK Recent Development Table 42. Teva Pharmaceuticals Inc Company Information Table 43. Teva Pharmaceuticals Inc Business Overview Table 44. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 46. Teva Pharmaceuticals Inc Recent Development Table 47. Eli Lilly and Company Company Information Table 48. Eli Lilly and Company Business Overview Table 49. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio Table 51. Eli Lilly and Company Recent Development Table 52. Pfizer Inc Company Information Table 53. Pfizer Inc Business Overview Table 54. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 56. Pfizer Inc Recent Development Table 57. Bayer AG Company Information Table 58. Bayer AG Business Overview Table 59. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio Table 61. Bayer AG Recent Development Table 62. United Therapeutic Corporation Company Information Table 63. United Therapeutic Corporation Business Overview Table 64. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio Table 66. United Therapeutic Corporation Recent Development Table 67. SteadyMed Ltd Company Information Table 68. SteadyMed Ltd Business Overview Table 69. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio Table 71. SteadyMed Ltd Recent Development Table 72. Gilead Sciences, Inc Company Information Table 73. Gilead Sciences, Inc Business Overview Table 74. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 76. Gilead Sciences, Inc Recent Development Table 77. Actelion Inc Company Information Table 78. Actelion Inc Business Overview Table 79. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 81. Actelion Inc Recent Development Table 82. North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Pulmonary Arterial Hypertension Treatment Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (US$ Million) & (2027-2032) Table 96. China Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 97. China Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 98. China Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 99. China Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Pulmonary Arterial Hypertension Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Pulmonary Arterial Hypertension Treatment Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Pulmonary Arterial Hypertension Treatment Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension Treatment Image Figure 2. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vasodilators Image Figure 5. Endothelin Receptor Antagonists (ERA) Image Figure 6. Phosphodiesterase 5 (PDE 5) Inhibitors Image Figure 7. Soluble Guanylate Cyclase (SGC) Stimulator Image Figure 8. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Pulmonary Arterial Hypertension Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacies Image Figure 11. Online Pharmacies Image Figure 12. Retail Pharmacies Image Figure 13. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Pulmonary Arterial Hypertension Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Pulmonary Arterial Hypertension Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Arterial Hypertension Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Pulmonary Arterial Hypertension Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2021-2032) Figure 24. North America Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032) Figure 26. North America Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032) Figure 27. North America Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2021-2032) Figure 28. United States Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032) Figure 45. China Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Pulmonary Arterial Hypertension Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Pulmonary Arterial Hypertension Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Vasodilators
  • Endothelin Receptor Antagonists (ERA)
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulator
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Teva Pharmaceuticals Inc
  • Eli Lilly and Company
  • Pfizer Inc
  • Bayer AG
  • United Therapeutic Corporation
  • SteadyMed Ltd
  • Gilead Sciences, Inc
  • Actelion Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pulmonary Arterial Hypertension Treatment Market by Type
  3. 1.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vasodilators
  5. 1.2.3 Endothelin Receptor Antagonists (ERA)
  6. 1.2.4 Phosphodiesterase 5 (PDE 5) Inhibitors
  7. 1.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
  8. 1.3 Pulmonary Arterial Hypertension Treatment Market by Application
  9. 1.3.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacies
  11. 1.3.3 Online Pharmacies
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Pulmonary Arterial Hypertension Treatment Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension Treatment Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension Treatment Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pulmonary Arterial Hypertension Treatment Market Perspective (2021-2032)
  2. 3.2 Global Pulmonary Arterial Hypertension Treatment Growth Trends by Region
  3. 3.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Players
  2. 4.1.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pulmonary Arterial Hypertension Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pulmonary Arterial Hypertension Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pulmonary Arterial Hypertension Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Pulmonary Arterial Hypertension Treatment Players, Product Type & Application
  8. 4.5 Global Pulmonary Arterial Hypertension Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pulmonary Arterial Hypertension Treatment Market CR5 and HHI
  11. 4.6.3 2025 Pulmonary Arterial Hypertension Treatment Tier 1, Tier 2, and Tier 3
5 Pulmonary Arterial Hypertension Treatment Market Size by Type
  1. 5.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2021-2032)
6 Pulmonary Arterial Hypertension Treatment Market Size by Application
  1. 6.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK Pulmonary Arterial Hypertension Treatment Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Teva Pharmaceuticals Inc
  8. 7.2.1 Teva Pharmaceuticals Inc Company Information
  9. 7.2.2 Teva Pharmaceuticals Inc Business Overview
  10. 7.2.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  12. 7.2.5 Teva Pharmaceuticals Inc Recent Developments
  13. 7.3 Eli Lilly and Company
  14. 7.3.1 Eli Lilly and Company Company Information
  15. 7.3.2 Eli Lilly and Company Business Overview
  16. 7.3.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio
  18. 7.3.5 Eli Lilly and Company Recent Developments
  19. 7.4 Pfizer Inc
  20. 7.4.1 Pfizer Inc Company Information
  21. 7.4.2 Pfizer Inc Business Overview
  22. 7.4.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  24. 7.4.5 Pfizer Inc Recent Developments
  25. 7.5 Bayer AG
  26. 7.5.1 Bayer AG Company Information
  27. 7.5.2 Bayer AG Business Overview
  28. 7.5.3 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio
  30. 7.5.5 Bayer AG Recent Developments
  31. 7.6 United Therapeutic Corporation
  32. 7.6.1 United Therapeutic Corporation Company Information
  33. 7.6.2 United Therapeutic Corporation Business Overview
  34. 7.6.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio
  36. 7.6.5 United Therapeutic Corporation Recent Developments
  37. 7.7 SteadyMed Ltd
  38. 7.7.1 SteadyMed Ltd Company Information
  39. 7.7.2 SteadyMed Ltd Business Overview
  40. 7.7.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio
  42. 7.7.5 SteadyMed Ltd Recent Developments
  43. 7.8 Gilead Sciences, Inc
  44. 7.8.1 Gilead Sciences, Inc Company Information
  45. 7.8.2 Gilead Sciences, Inc Business Overview
  46. 7.8.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  48. 7.8.5 Gilead Sciences, Inc Recent Developments
  49. 7.9 Actelion Inc
  50. 7.9.1 Actelion Inc Company Information
  51. 7.9.2 Actelion Inc Business Overview
  52. 7.9.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  54. 7.9.5 Actelion Inc Recent Developments
8 North America
  1. 8.1 North America Pulmonary Arterial Hypertension Treatment Revenue (2021-2032)
  2. 8.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Pulmonary Arterial Hypertension Treatment Revenue by Country
  11. 8.6.1 North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Pulmonary Arterial Hypertension Treatment Revenue (2021-2032)
  2. 9.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pulmonary Arterial Hypertension Treatment Revenue by Country
  11. 9.6.1 Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Pulmonary Arterial Hypertension Treatment Revenue (2021-2032)
  2. 10.2 China Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032)
  5. 10.3 China Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032)
  9. 10.5 China Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pulmonary Arterial Hypertension Treatment Revenue (2021-2032)
  2. 11.2 Asia Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pulmonary Arterial Hypertension Treatment Revenue by Country
  11. 11.6.1 Asia Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pulmonary Arterial Hypertension Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pulmonary Arterial Hypertension Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country
  11. 12.6.1 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pulmonary Arterial Hypertension Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst